You are here

Home » Content

Otozomal Dominant Polikistik Böbrek Hastalarında Arteriyel Sertlik ile s-Klotho ve FGF23 Düzeyleri Arasındaki İlişki

Relationship Between Arterial Stiffness and s-Klotho, FGF23 Levels in Autosomal Dominant Polycystic Kidney Disease Patients

Journal Name:

  • Akdeniz Tıp Dergisi

Publication Year:

  • 2017
DOI: 
10.17954/amj.2017.76

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: In this cross-sectional study, we investigated the relationship between soluble Klotho levels, FGF23 levels and arterial stiffness in Autosomal Dominant Polycystic Kidney Disease patients. Material and Methods: 74 patients (mean age: 50.92 ± 15.70 years) with autosomal Dominant Polycystic Kidney Disease and 32 healthy controls (mean age: 49.53 ± 7.32 years) were included in the study. Blood samples were collected to measure the levels of soluble Klotho, FGF23, serum creatinine, Calcium, Phosphorus and parathyroid hormone. Brachial artery pulse wave velocity and blood pressure were also measured using a combined monitor. Results: Soluble Klotho, FGF23 and parathyroid hormone levels were significantly higher in the patients than in controls (p<0.001). Systolic blood pressure, diastolic blood pressure (p<0.001 and brachial artery pulse wave velocity were also significantly higher in the patients (p=0.022). A positive correlation was found between soluble Klotho and brachial artery pulse wave velocity (r = 0.210, p=0.036) levels and FGF23 and brachial artery pulse wave velocity (r=0.245, p=0.014) levels. Conclusion: Arterial stiffness increased in Autosomal Dominant Polycystic Kidney Disease patients and was related to s-Klotho and FGF23 levels.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Bu kesitsel çalışmada; Otozomal Dominant Polikistik Böbrek hastalarında soluble Klotho, FGF23 düzeyleri ile arteriyel sertlik arasındaki ilişki incelenmiştir. Gereç ve Yöntemler: Otozomal Dominant Polikistik Böbrek Hastalığı (ODPBH) tanısı olan 74 hasta (ortalama yaş:50,92±15,70 yıl) ve 32 sağlıklı kontol (ortalama yaş:49,53±7,32 yıl) çalışmaya alınmıştır. Kan örnekleri soluble Klotho, FGF23, serum kreatinin, Kalsiyum, Fosfor ve Parathormon ölçümleri için toplanmıştır. Brakial arter nabız dalga hızı ve kan basıncı aynı monitör kullanılarak ölçülmüştür. Bulgular: Soluble Klotho, FGF23 ve Parathormon düzeyleri hastalarda kontrol grubuna göre anlamlı yüksek saptanmıştır (p<0,001). Aynı zamanda hasta grubunda sistolik kan basıncı, diyastolik kan basıncı (p<0,001) ve brakial arter nabız dalga hızı anlamlı yüksek saptanmıştır (p=0,022). Soluble Klotho ve brakial arter nabız dalga hızı (r = 0,210, p=0,036) düzeyleri, FGF23 ve brakial arter nabız dalga hızı (r=0,245, p=0,014) düzeyleri arasında pozitif korrelasyon saptanmıştır. Sonuç: Otozomal Dominant Polikistik Böbrek hastalarında arteriyel sertlik artar ve soluble Klotho, FGF23 düzeyleri ile ilişkili bulunmuştur.
FULL TEXT (PDF): 
PDF icon arastirmax-otozomal-dominant-polikistik-bobrek-hastalarinda-arteriyel-sertlik-ile-s-klotho-fgf23-duzeyleri-arasindaki-iliski.pdf
  • 2
89
95
  • Turkish

REFERENCES

References: 

1. Davies F, Coles GA, Harper PS, Williams AJ, Evans C,
Cochlin D. Polycystic kidney disease re-evaluated: A
population-based study. Q J Med 1991;79(290):477-85.
2. Gabow PA. Autosomal dominant polycystic kidney
disease. N Engl J Med. 1993;329(5):332-42.
3. Torres VE, Harris PC, Pirson Y. Autosomal dominant
polycystic kidney disease. Lancet 2007;369:1287-1301.
4. Ecder T, Schrier RW. Cardiovascular abnormalities in
autosomal-dominant polycystic kidney disease. Nat Rev
Nephrol 2009;5:221-8.
5. Masoumi A, Elhassan E, Schrier RW. Interpretation of
renal volume in autosomal dominant polycystic kidney
disease and relevant clinical implications. Iran J Kidney
Dis 2011;5:1-8.
6. Wang Y, Sun Z. Current understanding of Klotho. Ageing
Res Rev 2009; 8: 43-51.
93
Otozomal Dominant Polikistik Böbrek Hastalarında Arteriyel Sertlik ile s-Klotho ve FGF23 Düzeyleri Arasındaki İlişki
Akd Tıp D / Akd Med J / 2017; 2: 89-93
7. Komaba H, Fukagawa M. The role of FGF23 in CKDwith
or without Klotho. Nat Rev Nephrol 2012; 8: 484-90.
8. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue
K, Ogawa A, Yamanari T, Kikumoto Y, Uchida HA,
Kitamura S, Maeshima Y, Nakamura K, Ito H, Makino
H. A decreased level of serum soluble Klotho is an
independent biomarker associated with arterial stiffness in
patients with chronic kidney disease. PLoS One 2013; 8:
e56695.
9. Covic A, Florea L, Gusbeth-Tatomir P, Goldsmith DJ.
Arteriall stiffness in renal patients: An update. AJKD
2005; 45(6): 965–77.
10. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating
fibroblast growth factor-23 is associated with vascular
dysfunction in the community. Atherosclerosis 2009;
205:385-90.
11. DeLoach SS, Townsend RR: Vascular stiffness: Its
measurement and significance for epidemiologic and
outcome studies. Clin J Am Soc Nephrol 2008; 3 (1):
184-92.
12. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai
T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity,
reproducibility, and clinical significance of noninvasive
brachial-ankle pulse wave velocity measurement.
Hypertens Res 2002; 25: 359-364.
13. Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda
S, Koyama H, Emoto M, Nishizawa Y. Brachial-ankle
pulse wave velocity as an index of central arterial stiffness.
J Atheroscler Thromb 2010; 17: 658-65.
14. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder
D, Hsiao LL. Vascular Klotho deficiency potentiates the
development of human artery calcification and mediates
resistance to fibroblast growth factor 23. Circulation
2012; 125: 2243-55.
15. Hu MC, Shi M, Zhang J, Quiñones H, Griffith C,
Kuro-o M, Moe OW. Klotho deficiency causes vascular
calcification in chronic kidney disease. J Am Soc Nephrol
2011; 22: 124-36.
16. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa
H, Suga T, Matsumura Y, Masuda H, Kurabayashi M,
Kuro-o M, Nabeshima Y, Nagai R. Klotho protein
protects against endothelial dysfunction. Biochem Biophys
Res Commun 1998; 248: 324-9.
17. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler
AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O,
Wüthrich RP, Schmid C, Serra AL. Soluble Klotho and
autosomal dominant polycystic kidney disease. Clin J Am
Soc Nephrol 2012;7:248-57.
18. Sari F, Inci A, Dolu S, Ellidag HY, Cetinkaya R, Ersoy
FF. High serum soluble α-Klotho levels in patients with
autosomal dominant polycystic kidney disease. J Investig
Med 2016;65(2):358-62.
19. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova
T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare
JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman
EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR,
Feldman HI, St John Sutton M, Ojo A, Gadegbeku C,
Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand
M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG,
Wolf M. FGF23 induces left ventricular hypertrophy. J
Clin Invest. 2011;121:4393-408.
20. Yildiz A, Gul CB, Ersoy A, Asiltas B, Ermurat S, Dogan
S, Karaagac K, Sag S, Oruc A, Aktas N, Ocakoglu G,
Dogan I, Gullulu S, Gullulu M. Arterial Dysfunction in
Early Autosomal Dominant Polycystic Kidney Disease
Independent of Fibroblast Growth Factor 23.Iranian
Journal of Kidney Diseases; Tehran 8.6. 2014: 443-9

Thank you for copying data from http://www.arastirmax.com